Allogeneic hematopoietic-cell transplantation (allo-HCT) is widely used in the management of acquired and inherited disorders such as hematopoietic malignancies and in recent years for autoimmune and ...
Despite improvement in preventive measures, about 50% of allogeneic-HSCT patients develop acute GvHD (aGvHD) [1]. Acute GvHD has significant impact on outcomes after allogeneic-HSCT as well as on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results